Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study

NCT04725812 is registered in ClinicalTrials.gov with Cedars-Sinai Medical Center as lead sponsor.

NCT NCT04725812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04725812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study
Lead sponsor
Cedars-Sinai Medical Center
Phase
Phase 2
Overall status
Terminated
Start date
September 13, 2021
Completion date
December 7, 2021
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ahus, complement abnormality, complement regulatory factor defect, eculizumab, hellp, hellp syndrome, hellp syndrome second trimester, hellp syndrome third trimester, pnh, preeclampsia, pregnancy related, severe preeclampsia